Cargando…

COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery

Stupp regimen is widely used as the standard treatment after glioblastoma surgery, but in some cases treatment must be discontinued for various reasons. We experienced Bevacizumab in two patients who were unable to continue treatment in the Stupp regimen, and report our experience with literature re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kon, Takashi, Imaizumi, Yoichi, Kobayashi, Yusuke, Sato, Yosuke, Shimizu, Katsuyoshi, Mizutani, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699073/
http://dx.doi.org/10.1093/noajnl/vdaa143.097
_version_ 1783615965260414976
author Kon, Takashi
Imaizumi, Yoichi
Kobayashi, Yusuke
Sato, Yosuke
Shimizu, Katsuyoshi
Mizutani, Tohru
author_facet Kon, Takashi
Imaizumi, Yoichi
Kobayashi, Yusuke
Sato, Yosuke
Shimizu, Katsuyoshi
Mizutani, Tohru
author_sort Kon, Takashi
collection PubMed
description Stupp regimen is widely used as the standard treatment after glioblastoma surgery, but in some cases treatment must be discontinued for various reasons. We experienced Bevacizumab in two patients who were unable to continue treatment in the Stupp regimen, and report our experience with literature review. First patient is a man in his 60s. Resection of glioblastoma of the left cerebral hemisphere was performed, and postoperatively right hemiparesis and aphasia remained. Irradiation and administration of Temozolomide were performed, but Temozolomide was unable to continue because of side effects. After systemic management, Bevacizumab was administered, and reduction of residual tumor and peripheral edema were observed, and the patient began to speak. After 12 cycles of administration, the tumor regrew, and he died. Second patient is a woman in her 80s. Craniotomy was performed for hemorrhagic infarction of the left cerebral hemisphere, postoperatively, aphasia, right hemiparesis remained, bedridden, and was unable to eat. Four months after initial surgery, a tumor was found in left parietal lobe and was resected. The pathological diagnosis was glioblastoma. For the treatment of recurrence, the patient was unable to be transferred for radiochemotherapy, so the patient was treated with Temozolomide and Bevacizumab. The patient’s condition became better, eat by herself, and could play in rehabilitation facility on the wheelchair. After 12 cycles of bevacizumab, the tumor subsequently enlarged, and died. Although the effect is limited, there are some cases in which Bevacizumab administration could maintain patient’s condition by controlling tumor growth for a certain period of time. From the experience of these patients, it seems that even in patients with postoperative poor Karnofsky Performance Status (KPS)and elderly people, Bevacizumab administration would be an option before transitioning to end-of-life care.
format Online
Article
Text
id pubmed-7699073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-76990732020-12-02 COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery Kon, Takashi Imaizumi, Yoichi Kobayashi, Yusuke Sato, Yosuke Shimizu, Katsuyoshi Mizutani, Tohru Neurooncol Adv Supplement Abstracts Stupp regimen is widely used as the standard treatment after glioblastoma surgery, but in some cases treatment must be discontinued for various reasons. We experienced Bevacizumab in two patients who were unable to continue treatment in the Stupp regimen, and report our experience with literature review. First patient is a man in his 60s. Resection of glioblastoma of the left cerebral hemisphere was performed, and postoperatively right hemiparesis and aphasia remained. Irradiation and administration of Temozolomide were performed, but Temozolomide was unable to continue because of side effects. After systemic management, Bevacizumab was administered, and reduction of residual tumor and peripheral edema were observed, and the patient began to speak. After 12 cycles of administration, the tumor regrew, and he died. Second patient is a woman in her 80s. Craniotomy was performed for hemorrhagic infarction of the left cerebral hemisphere, postoperatively, aphasia, right hemiparesis remained, bedridden, and was unable to eat. Four months after initial surgery, a tumor was found in left parietal lobe and was resected. The pathological diagnosis was glioblastoma. For the treatment of recurrence, the patient was unable to be transferred for radiochemotherapy, so the patient was treated with Temozolomide and Bevacizumab. The patient’s condition became better, eat by herself, and could play in rehabilitation facility on the wheelchair. After 12 cycles of bevacizumab, the tumor subsequently enlarged, and died. Although the effect is limited, there are some cases in which Bevacizumab administration could maintain patient’s condition by controlling tumor growth for a certain period of time. From the experience of these patients, it seems that even in patients with postoperative poor Karnofsky Performance Status (KPS)and elderly people, Bevacizumab administration would be an option before transitioning to end-of-life care. Oxford University Press 2020-11-28 /pmc/articles/PMC7699073/ http://dx.doi.org/10.1093/noajnl/vdaa143.097 Text en © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Kon, Takashi
Imaizumi, Yoichi
Kobayashi, Yusuke
Sato, Yosuke
Shimizu, Katsuyoshi
Mizutani, Tohru
COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
title COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
title_full COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
title_fullStr COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
title_full_unstemmed COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
title_short COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
title_sort cot-11 administration of bevacizumab for patients who failed to complete stupp regimen after glioblastoma surgery
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699073/
http://dx.doi.org/10.1093/noajnl/vdaa143.097
work_keys_str_mv AT kontakashi cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery
AT imaizumiyoichi cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery
AT kobayashiyusuke cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery
AT satoyosuke cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery
AT shimizukatsuyoshi cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery
AT mizutanitohru cot11administrationofbevacizumabforpatientswhofailedtocompletestuppregimenafterglioblastomasurgery